Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML

2.

Döhner

H

,

DiNardo

CD

,

Appelbaum

F

, et al.

Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations

.

Blood

.

2024

;

144

(

21

):

2169

-

2173

.

3.

Bataller

A

,

Bazinet

A

,

DiNardo

CD

, et al.

Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax

.

Blood Adv

.

2024

;

8

(

4

):

927

-

935

.

4.

Pratz

KW

,

Jonas

BA

,

Pullarkat

V

, et al.

Long-term follow-up of VIALE-A: venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia

.

Am J Hematol

.

2024

;

99

(

4

):

615

-

624

.

5.

Chua

CC

,

Hammond

D

,

Kent

A

, et al.

Treatment-free remission after ceasing venetoclax-based therapy in patients with acute myeloid leukemia

.

Blood Adv

.

2022

;

6

(

13

):

3879

-

3883

.

6.

Othman

J

,

Tiong

IS

,

O'Nions

J

, et al.

Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy

.

Blood

.

2024

;

143

(

4

):

336

-

341

.

7.

Garciaz

S

,

Dumas

PY

,

Bertoli

S

, et al.

Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatment

.

Am J Hematol

.

2024

;

99

(

10

):

1870

-

1876

.

8.

DiNardo

CD

,

Tiong

IS

,

Quaglieri

A

, et al.

Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML

.

Blood

.

2020

;

135

(

11

):

791

-

803

.

9.

Zhang

H

,

Nakauchi

Y

,

Köhnke

T

, et al.

Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia

.

Nat Cancer

.

2020

;

1

(

8

):

826

-

839

.

10.

Döhner

H

,

Wei

AH

,

Appelbaum

FR

, et al.

Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN

.

Blood

.

2022

;

140

(

12

):

1345

-

1377

.

11.

Matthews

AH

,

Perl

AE

,

Luger

SM

, et al.

Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia

.

Blood Adv

.

2022

;

6

(

13

):

3997

-

4005

.

12.

Abaza

Y

,

Winer

ES

,

Murthy

GS

, et al.

Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: real-world data from eight US academic centers

.

Am J Hematol

.

2024

;

99

(

4

):

606

-

614

.

13.

Winters

AC

,

Gutman

JA

,

Purev

E

, et al.

Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia

.

Blood Adv

.

2019

;

3

(

20

):

2911

-

2919

.

14.

Papaemmanuil

E

,

Gerstung

M

,

Bullinger

L

, et al.

Genomic classification and prognosis in acute myeloid leukemia

.

N Engl J Med

.

2016

;

374

(

23

):

2209

-

2221

.

15.

Othman

J

,

Lam

HP

,

Leong

S

, et al.

Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHS

.

Blood Neoplasia

.

2024

;

1

(

3

):

100017

.

16.

Hoff

FW

,

Blum

W

,

Huang

Y

, et al.

Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy

.

Blood Adv

.

2024

;

8

(

20

):

5297

-

5305

.

17.

Pollyea

DA

,

DiNardo

CD

,

Arellano

ML

, et al.

Impact of venetoclax and azacitidine in treatment-naïve patients with acute myeloid leukemia and IDH1/2 mutations

.

Clin Cancer Res

.

2022

;

28

(

13

):

2753

-

2761

.